In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer
diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora …

Nuclear medicine is expected to make major advances in cancer diagnosis and therapy;
tumor-targeted radiopharmaceuticals preferentially eradicate tumors while causing minimal …

Purpose: Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are
poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and …

Major advances in prostate cancer diagnosis, staging, and management have occurred over
the past decade, largely due to our improved understanding of the technical aspects and …

Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate
cancer frequently seen after prolonged treatment of castration resistant prostate cancer …

In recent years, the application of radionuclides‐containing nanomaterials in cancer
treatment has garnered widespread attention. The diversity of nanomaterials allows …

Prostate cancer (PCa) induced death is the predominant cause of cancer-related death
among men in 48 countries. After radical treatment, biochemical recurrence has become an …

Please see the Editorial Comment by Jabi Shriki discussing this article. PET with targeted
radiotracers has become integral to mapping the location and burden of recurrent disease in …

Background For men with prostate cancer, radiographic progression may occur without a
concordant rise in prostate‐specific antigen (PSA). Our study aimed to assess the …

目的采用超高效液相色谱-四级杆串联飞行时间质谱(UHPLC-Q-TOF/MS)
法分析恩杂鲁胺耐药的去势抵抗性前列腺癌细胞(CRPC) 原型成分及代谢产物 …